IL-17A + CTCs

Biomarker

1 finding

“The combination of IL-17 A and CTCs achieved an AUC of 0.953, with a sensitivity of 86.05% and specificity of 90.00%.”
Clinical value of CTCs combined with serum tumor markers/inflammatory cytokines for the early diagnosis of non-small cell lung cancerImmunobiology2026doi:10.1016/j.imbio.2026.153161

Associations

1

Non-small cell lung cancer

upin humans1

1 study
  1. IL-17A + CTCs predicts non-small cell lung cancer in humans (diagnosis of early-stage NSCLC) (AUC 0.953, sensitivity 86.05%, specificity 90.00%).

    Humansdiagnosis of early-stage NSCLCblood

More on Non-small cell lung cancer